Last reviewed · How we verify

NCT06256523

A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Completed Phase 1, PHASE2 Last updated 23 February 2024
What this trial tests

Phase 1, PHASE2 trial testing GZR18 in Type 2 Diabetes in 72 participants. Completed in 28 September 2023.

Timeline
29 June 2022
Primary endpoint
28 September 2023
28 September 2023

Quick facts

Lead sponsorGan and Lee Pharmaceuticals, USA
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment72
Start date29 June 2022
Primary completion28 September 2023
Estimated completion28 September 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Gan and Lee Pharmaceuticals, USA — full company profile →

Who can join

Adults 18 to 65, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled Phase Ib/IIa clinical study in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise and/or treated with irregular use of antidiabetic drugs to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in adult subjects with T2DM. This study is divided into Part A and Part B, which are to be conducted simultaneously.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of GZR18

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Gan and Lee Pharmaceuticals, USA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06256523.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing